Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2017 | How can we describe atypical Alzheimer’s pathology?

Melissa Murray • 29 Aug 2017
AAIC 2017
Alzheimer’s Disease

The heterogeneous nature of Alzheimer’s disease (AD) can make it difficult to understand the disorder’s pathology. Melissa Murray, PhD from the Mayo Clinic, Jacksonville, FL talks to us about her presentation at the 2017 Alzheimer’s Association International Conference (AAIC) in London, UK, which emphasized the multiple ways which can be used to describe atypical AD pathology. Dr Murray also describes some of the different pathologies of AD, and speaks about a study involving a brain bank in Florida.

More from Melissa Murray

Shaping future care: biomarker advances in Alzheimer’s Disease
2:24
Shaping future care: biomarker advances in Alzheimer’s Disease
Melissa Murray • 7 Mar 2024
Neuroimaging and fluid biomarkers in early-onset Alzheimer’s disease
1:01
Neuroimaging and fluid biomarkers in early-onset Alzheimer’s disease
Melissa Murray • 7 Mar 2024
LEADS: shedding light on early-onset Alzheimer's disease
1:53
LEADS: shedding light on early-onset Alzheimer's disease
Melissa Murray • 7 Mar 2024
Quantifying tau pathology patterns in young-onset Alzheimer’s disease
4:20
Quantifying tau pathology patterns in young-onset Alzheimer’s disease
Melissa Murray • 7 Mar 2024

Related Videos

A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
10:28
A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
Muhammad Umar Khan • 28 Aug 2026
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
3:25
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
Vikash Jaiswal • 26 Aug 2026
What are the biological mechanisms underlying the higher prevalence of AD in women?
1:55
What are the biological mechanisms underlying the higher prevalence of AD in women?
Amber Watts • 14 Jul 2026
MenoCog: risk and protective factors for cognitive function in the menopause transition
2:37
MenoCog: risk and protective factors for cognitive function in the menopause transition
Amber Watts • 14 Jul 2026

Choose your cookie settings

VJDementia uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJDementia is intended for healthcare professionals